Formed in 1996, BioKinetic has been at the fore of early phase drug development for over 19 years. The company has been steadily increasing in size, now employing over 40 full-time members of staff operating to the UK regulatory body’s (MHRA) highest standard of Supplementary Accreditation. BioKinetic Europe has developed a reputation for meticulously managed Phase I —Ill studies on behalf of pharmaceutical companies in Europe, Asia and the United States. BioKinetic is a FPM (Faculty of Pharmaceutical Medicine) approved educational training unit, with a range of Principal Investigators and Clinical Research Professionals with experience and expertise across all therapeutic areas.
Feasibility & Study Award
Database lock, review of CSR, study close-out